By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ACADIA Pharmaceuticals, Inc. 

3911 Sorrento Valley Boulevard

San Diego  California  92121   U.S.A.
Phone: 858-558-2871 Fax: 858-558-2872


Drug Discovery


Allergan  Discovery of alpha adrenergic drug candidates that may represent a significant breakthrough in the treatment of neuropathic pain.

Allergan  Develop and commercialize selective muscarinic drugs for the treatment of glaucoma.

Allergan  The third collaboration is designed to leverage ACADIA's R&D platform to discover and develop new therapeutics predominantly in the area of pain.

Sunovion Pharmaceuticals Inc.  ACADIA has formed a broad CNS collaboration with Sepracor for the discovery and development of new drug candidates against muscarinic receptors.

Company News
Acadia (ACAD) To Present At The JMP Securities Life Sciences Conference On June 24, 2015 6/17/2015 10:11:24 AM
Acadia (ACAD) Presents Integrated Data From Its Phase III Program With NUPLAZID (Pimavanserin) For Parkinson’s Disease Psychosis At The b>19th International Congress Of Parkinson’s Disease And Movement Disorders 6/16/2015 9:53:09 AM
Acadia (ACAD) To Present At The Jefferies and Co. 2015 Healthcare Conference On June 2, 2015 5/26/2015 11:12:09 AM
Acadia (ACAD) Reports First Quarter 2015 Financial Results 5/8/2015 11:38:48 AM
Acadia (ACAD) To Present At The Bank of America (BAC) Merrill Lynch 2015 Health Care Conference On May 13, 2015 5/6/2015 12:12:46 PM
Acadia (ACAD) To Announce First Quarter Financial Results On May 7, 2015 4/30/2015 12:50:48 PM
As AbbVie (ABBV) Eyes Alzheimer's Franchise, Speculation Mounts About a $4.5B Marriage to Acadia (ACAD) 4/8/2015 8:54:02 AM
Acadia (ACAD) To Present At The 14th Annual Needham Healthcare Conference On April 14, 2015 4/7/2015 10:57:23 AM
Acadia (ACAD) Appoints Daniel Soland To Board Of Directors 3/26/2015 8:40:19 AM
Acadia (ACAD) Updates Planned Timing Of NUPLAZID NDA Submission 3/12/2015 7:51:00 AM